首页> 外文期刊>Endocrine journal >Can We Use Plasma Fibronectin Levels as a Marker for Early Diabetic Nephropathy
【24h】

Can We Use Plasma Fibronectin Levels as a Marker for Early Diabetic Nephropathy

机译:我们能否使用血浆纤连蛋白水平作为早期糖尿病肾病的标志物

获取原文
       

摘要

References(32) Although increased plasma fibronectin (PF) levels have been found in diabetic patients with microalbuminuria, there is still controversy about its clinical implication for detecting early diabetic nephropathy. To evaluate the PF concentration as a possible marker for early diabetic nephropathy, three groups of sex-and age-matched patients were studied I) 22 insulin dependent diabetic (IDDM) patients with microalbuminuria (mean age±SEM: 23.3±3.6 years, mean urinary albumin excretion rate (AER)±SEM: 47.1±39.5μg/min); II) 17 IDDM patients with normoalbuminuria (mean age: 23.4±4.4 years, mean AER: 7.8±2.1μg/min) and III) 20 healthy control subjects (mean age: 22.6±4.1 years, mean AER: 6.7±2.1μg/min). PF and urinary excretion of albumin were measured by an immunoturbidimetric method using commercially available kits (Boehringer Mannheim GMBH FRG, and Miles Lab., UK). The mean PF was significantly higher in the group with microalbuminuria (406.5±122.9μg/ml) than in the group with normoalbuminuria (295.6±96.9μg/ml, P0.01) or in the control group (299.54±105.5 μg/ml, P0.01). A weak positive correlation was found between PF and urinary albumin values (r=0.35, P0.05). There were no significant correlations between PF and the other variables such as age, duration of diabetes, body mass index, arterial blood pressure, fasting blood glucose, fructosamine and HbA1 in the diabetic patients or in the control group. Our results suggest that the PF concentration could be a weak marker for early diabetic nephropathy. We cannot therefore use PF instead of microalbuminuria because there is only a weak correlation between PF and microalbuminuria.
机译:参考文献(32)尽管在患有微量白蛋白尿的糖尿病患者中发现血浆纤连蛋白(PF)水平升高,但其在检测早期糖尿病肾病中的临床意义仍存在争议。为了评估PF浓度作为早期糖尿病肾病的可能标志物,研究了三组性别和年龄匹配的患者:I)22名胰岛素依赖型糖尿病(IDDM)糖尿病患者伴有微量白蛋白尿(平均年龄±SEM:23.3±3.6岁,平均尿白蛋白排泄率(AER)±SEM:47.1±39.5μg/ min); II)17名IDDM的白蛋白尿患者(平均年龄:23​​.4±4.4岁,平均AER:7.8±2.1μg/ min)和III)20名健康对照组(平均年龄:22.6±4.1岁,平均AER:6.7±2.1μg/ min分钟)。使用市售试剂盒(Boehringer Mannheim GMBH FRG和Miles Lab。,英国)通过免疫比浊法测量PF和尿白蛋白排泄量。微量白蛋白尿组(406.5±122.9μg/ ml)的平均PF显着高于正常白蛋白尿组(295.6±96.9μg/ ml,P <0.01)或对照组(299.54±105.5μg/ ml), P <0.01)。 PF与尿白蛋白值之间呈弱正相关(r = 0.35,P <0.05)。在糖尿病患者或对照组中,PF与其他变量之间没有显着相关性,例如年龄,糖尿病持续时间,体重指数,动脉血压,空腹血糖,果糖胺和HbA1。我们的结果表明,PF浓度可能是早期糖尿病肾病的弱标志。因此,我们不能使用PF代替微量白蛋白尿,因为PF和微量白蛋白尿之间只有很弱的相关性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号